Prospective Identification of Variables As Outcomes for Treatment (PIVOT): A Phase II Clinical Trial of Hydroxyurea for Children and Adults with HbSC Disease

MLA

Segbefia, Catherine I., et al. “Prospective Identification of Variables As Outcomes for Treatment (PIVOT): A Phase II Clinical Trial of Hydroxyurea for Children and Adults with HbSC Disease.” Blood, vol. 142, no. 1, Number 1 Supplement 1, Nov. 2023, p. 3877. EBSCOhost, https://doi.org/10.1182/blood-2023-190351.

APA

Segbefia, C. I., Smart, L. R., Stuber, S. E., Ekpale, P., Amissah-Arthur, K. N., Dzefi-Tettey, K., Mensah, E., Lane, A. C., Dwuma-Badu, D., Latham, T. S., Dei-Adomakoh, Y., & Ware, R. E. (2023). Prospective Identification of Variables As Outcomes for Treatment (PIVOT): A Phase II Clinical Trial of Hydroxyurea for Children and Adults with HbSC Disease. Blood, 142(1, Number 1 Supplement 1), 3877. https://doi.org/10.1182/blood-2023-190351

Chicago

Segbefia, Catherine I., Luke R. Smart, Susan E. Stuber, Priscilla Ekpale, Kwesi N. Amissah-Arthur, Klenam Dzefi-Tettey, Enoch Mensah, et al. 2023. “Prospective Identification of Variables As Outcomes for Treatment (PIVOT): A Phase II Clinical Trial of Hydroxyurea for Children and Adults with HbSC Disease.” Blood 142 (1, Number 1 Supplement 1): 3877. doi:10.1182/blood-2023-190351.